Treating Body and Mind in Atopic Dermatitis: Priorities for Primary Care
Psychiatric comorbidities affect 25% of AD patients. Here, a check list on when to screen, when to refer, and how to prevent accumulated psychological burden in primary care.
Merck Secures Fast Track for Novel AD Antibody and Reports First-in-Human Data
New safety and biomarker results from MK-2214 and MK-1167 advance Merck’s dual approach to Alzheimer therapy.
Galcanezumab Efficacy and Safety Confirmed in Meta-Analysis of Real-World Studies
Two-thirds of participants experienced clinically meaningful response within 3 months; effects sustained through 12 months with mild adverse event profile.
Evolocumab Associated with Lower Long-term Cardiovascular Event Risk in Real-world Study of More Than 110 000 Patients
New data reveals evolocumab significantly reduces long-term major cardiovascular event risks in ASCVD patients, enhancing treatment strategies for better outcomes.
FDA's Vaccine Chief Prasad Links Pediatric Deaths to COVID-19 Shots, Proposes Stricter Regulatory Framework
Former CBER chief calls claims "misrepresentation." ID experts Offit and Osterholm criticize timing ahead of CDC advisory committee meeting next week.
Geriatric NP Carolyn Clevenger Discusses Agitation in Alzheimer Disease: Overlooked, Misunderstood, and Progressive
Clevenger reviews survey findings behind the recent report "The Agitation Blindspot in Alzheimer’s Care."
Atopic Dermatitis Management Beyond Skin Symptoms in Primary Care
A regular focus on mental heatlh during follow-ups with patients who have atopic dermatitis can be integrated simply with a few thoughtful questions.
Benzodiazepines, Antipsychotics Linked to Increased Death in Dementia Hospice: Daily Dose
Your daily dose of the clinical news you may have missed.
Meta-Analysis Finds High Uptake but Moderate Adherence in Clinical Trials of Depression and Anxiety Apps
Mental health apps show high initial uptake but moderate adherence, revealing key factors for improving user retention in clinical trials.
Novo Nordisk Seeks FDA Approval for Higher-Dose Semaglutide 7.2 mg for Chronic Weight Management
Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.
Primary Care Training Boosts LARC Uptake and Long-Term Retention: Daily Dose
Otsuka Submits NDA to FDA for Centanafadine for Treatment of ADHD Across the Lifespan
Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.
FDA Approves Itvisma, First Gene Therapy for Older Children and Adults With Spinal Muscular Atrophy
Novartis's Itvisma gains FDA approval as the first intrathecal gene therapy for spinal muscular atrophy, promising improved motor function and independence.
Atopic Dermatitis Signs and Symptoms for Referral: Physical and Emotional Expertise
Primary care is the ideal setting for management of atopic dermatitis, but certain scenarios, both physical and psychological, call for expert referral.
Long-Term Smoking Cessation Slows Cognitive Decline in Adults: Daily Dose
J&J's Investigational Anti-Tau Alzheimer Drug Posdinemab Fails to Meet Primary Endpoint in Phase 2b Trial
J&J halts phase 2b AuTonomy trial after anti-tau antibody posdinemab fails to slow clinical decline, marking another setback for tau-targeting therapeutics.
2025-2026 Flu Season: Reduced Vaccine Match May Lead to Increased Transmission and Severity, Experts Warn
The H3N2 subclade K is dominating early flu season gobally; despite vaccine mismatch, vaccination remains the primary defense against severe illness and hospitalization.
HPV Vaccination Strongly Reduces Cervical Cancer Risk, New Cochrane Reviews Confirm
Two new Cochrane reviews confirm HPV vaccines significantly reduce cervical cancer risk, especially when given before age 16, with no serious safety concerns.
Semaglutide Fails to Slow Progression of Alzheimer Disease Compared to Placebo: Novo Nordisk Phase 3 Trial Update
Evoke trials testing semaglutide for Alzheimer disease missed primary endpoint, failing to demonstrate benefit on cognition despite positive effects on disease markers.
Bayer's Asundexian Reduces Ischemic Stroke Risk Without Raising Major Bleeding in Phase III Trial
Topline data show the factor XIa inhibitor cut ischemic stroke risk without increasing ISTH major bleeding, pointing to a possible new option for secondary prevention.
Two-Thirds of Pregnancies Have Weight Gain Outside Recommended Ranges, Meta-Analysis of 1.6 Million Women Finds
A recent meta-analysis reveals that two-thirds of pregnancies experience unhealthy weight gain, highlighting risks for mothers and babies.
FDA Approves First New IPF Treatment in More Than a Decade: Daily Dose
Perimenopause Comes with "Feast-and-Famine" Swings in Hormone Levels, Says Gynecologist Bruce Dorr, MD
Dorr says symptoms can begin 10 years before cylces cease and explains why the hormonal feast and famine of perimenopause can go unrecognized.
Breaking the Silence: Discussing Menopause Treatment Options in Primary Care
Lisa Larkin, MD, discusses how social media is driving menopause awareness and why primary care physicians must educate themselves to meet patient demand.
Caffeinated Coffee Linked to Lower Atrial Fibrillation Recurrence in First-of-its-Kind Randomized Clinical Trial
New research reveals that caffeinated coffee significantly reduces the recurrence of atrial fibrillation, challenging long-held medical advice.
Lung Cancer Screening Guidelines in the US Miss Roughly Two-Thirds of Cases, New Study Finds
Universal age-based screening, starting at age 40, could detect more than 90% of tumors compared to risk-based screening, according to Feinberg School of Medicine researchers.
Intervene Early in AD to Avoid Lasting Psychological Impact
Controlling atopic dermatitis signs and symptoms early can alter social, emotional, and functional outcomes, sometimes dramatically.
Emotional Red Flags in Atopic Dermatitis: What to Screen For
Emotional red flags in AD, eg, sleep loss, isolation, hopelessness, often go unseen. Quick screening questions can surface the real burden individuals carry.
Atopic Dermatitis: The Lifetime Impact of the Condition
Growing up with AD carries lifelong emotional consequences. Clinicians who recognize these developmental risks can better support patients at every stage.
Mental Health Comorbidities in Atopic Dermatitis: Essential Insights for Primary Care
Up to 1 in 4 patients with atopic dermatitis face anxiety or depression. Primary care clinicians are key to identifying risk and supporting mental well-being.
